Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2019 Feb;58(1):345-356.
doi: 10.1007/s00394-017-1598-5. Epub 2017 Dec 18.

Effects of Folic Acid Supplementation on Cognitive Function and Aβ-related Biomarkers in Mild Cognitive Impairment: A Randomized Controlled Trial

Affiliations
Randomized Controlled Trial

Effects of Folic Acid Supplementation on Cognitive Function and Aβ-related Biomarkers in Mild Cognitive Impairment: A Randomized Controlled Trial

Fei Ma et al. Eur J Nutr. .

Abstract

Purpose: Observational studies have frequently reported that low blood folate concentrations are associated with poor cognitive performance. Our previous studies have shown the potential beneficial effect on the metabolite levels of methionine cycle and peripheral blood inflammatory cytokines from 6- and 12-month folic acid supplementation on cognitive function in mild cognitive impairment (MCI). This study aims to continue exploring the effect of 24-month folic acid supplementation on cognitive function and pathological mechanism in MCI.

Methods: 180 individuals with MCI were identified and randomly divided into intervention (folic acid 400 µg/day, n = 90) and convention (n = 90) groups. Cognitive function (WAIS-RC) and blood Aβ-related biomarkers were measured at baseline and at 6, 12, 18, and 24 months. Data were analyzed using generalized estimating equation. This trial has been registered with Trial Number: ChiCTR-TRC-13003227.

Results: During the follow-up, scores of full scale IQ, verbal IQ, and subdomains of Information and Digit Span were significantly higher in the intervention group than those in the convention group (P < 0.05). In the intervention group, blood homocysteine, S-adenosylhomocysteine (SAH), Aβ-42, and the expression of APP-mRNA were decreased (P < 0.05), while S-adenosylmethionine (SAM), SAM/SAH ratio, and the expression of DNA methyltransferase mRNA were increased (P < 0.05).

Conclusion: Folic acid supplementation appears to improve cognitive function and reduce blood levels of Aβ-related biomarkers in MCI. Larger-scale double-blind placebo-controlled randomized trials of longer duration are needed.

Keywords: Cognitive function; DNA methyltransferase; Folate; Mild cognitive impairment; Randomized controlled trial; β-Amyloid.

Similar articles

See all similar articles

Cited by 5 articles

References

    1. J Aging Health. 1993 May;5(2):179-93 - PubMed
    1. Nature. 1999 Jun 24;399(6738 Suppl):A23-31 - PubMed
    1. N Engl J Med. 1999 Nov 11;341(20):1485-90 - PubMed
    1. Arch Neurol. 2000 Jan;57(1):100-5 - PubMed
    1. Neurology. 2001 May 8;56(9):1133-42 - PubMed

Publication types

LinkOut - more resources

Feedback